Judge offers early win for Arbutus as Moderna vaccine patent spat heats up

A Delaware federal judge has sided with Arbutus’ interpretation of three patent claim terms in its case against Moderna, giving the biotech a small win in a drawn-out patent dispute.

Arbutus and Genevant filed suit against Moderna in 2022, alleging the company’s historic mRNA vaccine used lipid nanoparticle (LNP) technology developed and patented by Arbutus. While plaintiffs agreed that the Covid-19 pandemic would have been “immeasurably worse” without the widespread availability of Moderna’s vaccine, they argued that the achievement was made possible by Arbutus’ discoveries around LNPs.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。